UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 660 W. Germantown Pike, Suite 110 Plymouth Meeting, Pennsylvania 19462 (Address of principal executive offices) (Zip Code) (I.R.S. Employ ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Renza - Biotechnology Equity Research Analyst, RBC Conference Call Participants Jacqueline Shea - President & CEO Greg Renza Great. So welcome back to the 2023 RBC Global Healthcare Conference. My name is Greg Renza, I'm one of the biotechnology equity research analyst here at RBC and we're pleased now to be joined by Inovio Pharmaceuticals and representing the co ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Li Chen - H.C. Wainwright Operator Good day and welcome to the Inovio First Quarter 2022 Financial Results Conference Call. All participants will be in a l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of incorporation or organization) ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Oppenheimer 33rd Annual Healthcare Conference Call March 13, 2023 10:40 AM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great, thank you. Thanks always to the operators for making this so easy. Hey, everybody. I apologize for the little delay here. I just had a lack of a better term a brain fart. And we have Jacqueline Shea here with us with Inovio, representing t ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Thomas Hong - Manager-Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Charlie Young - Bank of America Yi Chen - H.C. Wainwright Operator Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being ...

Corporate Presentation November 2022 :INO Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements,"" within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...